How does Otezla (apremilast) work in the body?
Otezla’s mechanism of action is based on inhibition of the enzyme phosphodiesterase 4 (PDE4). By blocking PDE4, apremilast increases intracellular levels of cyclic AMP (cAMP). That shift in cAMP signaling changes downstream inflammatory pathways, which can reduce the release of pro-inflammatory mediators involved in conditions such as plaque psoriasis, psoriatic arthritis, and Behçet’s disease–associated oral ulcers [1].
What does PDE4 inhibition change, and why does that matter for inflammation?
PDE4 normally breaks down cAMP. When apremilast inhibits PDE4, cAMP levels rise, which affects signaling inside immune and inflammatory cells. This altered signaling leads to reduced production of inflammatory mediators and a broader shift toward an anti-inflammatory cytokine profile [1].
What conditions is Otezla linked to through this mechanism?
Otezla is used for inflammatory diseases where these cytokine and immune signaling pathways are central to symptoms, including plaque psoriasis, psoriatic arthritis, and Behçet’s disease–associated oral ulcers. Its PDE4/cAMP mechanism is the shared pharmacologic basis across these indications [1].
How is apremilast’s mechanism different from biologics?
Unlike biologic drugs that target specific cytokines (for example, individual interleukins or TNF), apremilast works upstream by modulating intracellular signaling through PDE4 inhibition and cAMP changes. That means it adjusts inflammatory signaling more indirectly through enzyme inhibition rather than binding a single external immune molecule [1].
Sources
[1] DrugPatentWatch.com – Otezla (apremilast) information: https://www.drugpatentwatch.com/p/drug/otezla-apremilast/